![]() |
市場調查報告書
商品編碼
2085945
體外震波碎石設備市場:2026-2032年全球市場預測(按產品類型、模式、成像方法、應用和最終用戶分類)Lithotripsy Devices Market by Product Type, Mode, Imaging Type, Application, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,體外震波碎石術市場規模將達到 20.4 億美元,複合年成長率為 5.05%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 14.4億美元 |
| 預計年份:2026年 | 15.1億美元 |
| 預測年份:2032年 | 20.4億美元 |
| 複合年成長率 (%) | 5.05% |
體外震波碎石設備在現代體外震波碎石術中發揮核心作用,能夠以非侵入性或微創方式粉碎腎結石、輸尿管結石、膀胱結石以及部分膽道結石。該市場涵蓋體外震波碎石系統、用於體內治療的雷射碎石平台、氣動和超音波碎石設備、一次性光纖和探針、具備成像功能的主機,以及醫院、門診手術中心和泌尿系統診所使用的各種服務模式。
臨床因素支持了這一需求,特別是尿道結石負擔的加重、結石復發、人口老化、肥胖、糖尿病、脫水風險、鹽和動物蛋白質攝取量的增加,以及內視鏡泌尿系統治療的普及。主要泌尿系統學會的臨床指南繼續將體外震波碎石術、雷射碎石輸尿管鏡碎石術和經皮腎鏡取石術列為核心治療方法,而器械的選擇越來越取決於結石的大小、位置、成分、解剖結構、感染情況以及醫護人員的經驗。
體外碎石設備的市場正在從單純購買醫療設備轉向整合式治療生態系統。醫院在評估各種平台時,不僅考慮結石清除效果,還關注手術室效率、減少透視次數、雷射光纖利用率、設備運轉率、培訓支援、與感染控制的兼容性以及總體擁有成本 (TCO)。這使得那些能夠提供耐用系統以及耗材、軟體、服務合約和臨床培訓的供應商更具優勢。
人工智慧 (AI) 正透過影像分析、工作流程自動化、預測分析和治療計畫等方式,開始影響體外震波碎石術 (ESW)。 AI 驅動的 CT 和超音波影像分析有助於結石檢測、結石體積估算、密度評估、結石距皮膚距離評估和解剖定位,從而幫助臨床醫生確定體外震波碎石術、輸尿管鏡輔助雷射碎石術或經皮治療哪種是最佳治療方案。
亞太地區是取石設備市場最活躍的地區之一,這得益於不斷完善的醫院基礎設施、龐大的病患群體,以及內視鏡泌尿系統在中國、印度、日本、韓國、澳洲和東協市場的日益普及。儘管由於三級醫療、醫療旅遊、專科培訓以及公共和私人對影像技術的投資,醫療保健的可及性正在不斷提高,但保險報銷差異、都市區差距以及先進雷射和衝擊波系統的分佈不均仍然是限制因素。
在東協市場,隨著都市區醫院微創手術能力的提升,輸尿管鏡檢查和雷射碎石術的應用日益普及。同時,採購環節往往優先考慮價格可負擔性、快速反應服務、耗材供應以及臨床醫生培訓。海灣合作理事會(GCC)成員國,尤其是沙烏地阿拉伯、阿拉伯聯合大公國、卡達和科威特,在醫療保健領域投入龐大,擁有先進的醫院網路,積極發展醫療旅遊,並且對高階泌尿系統系統有著強勁的需求。
美國仍然是最大的單一國家市場,這得益於其先進的泌尿系統網路、尖端的影像技術、廣泛的門診手術以及雷射碎石術在輸尿管結石治療中的廣泛應用。加拿大則憑藉醫院主導的採購和區域專科醫療中心,需求保持穩定。同時,墨西哥受益於都市區私立醫院的蓬勃發展、專科醫生診療管道的拓展以及跨境醫療服務的趨勢。巴西是拉丁美洲的核心市場,大規模的大都會圈醫院系統、私營部門的投資以及不斷成長的訓練有素的泌尿系統數量都為其發展提供了有力支撐。
行業領導者應根據每項手術的具體情況調整產品系列,以實現最佳價值。具體而言,應針對特定非侵入性病例採用體外震波碎石術,針對輸尿管鏡手術採用高性能雷射碎石術,以及針對經皮手術採用超音波或氣動碎石系統。供應商應投資於訓練計畫、模擬訓練、臨床支援、指導醫師訓練和標準化操作規程,以改善治療效果,縮短學習曲線,並確保碎石設備在醫院和門診環境中得到一致應用。
本執行摘要採用結構化的二手研究方法撰寫,優先參考同行評審的臨床文獻、泌尿系統指南、監管資料庫、公共衛生資訊來源、醫院調查方法模式、報銷參考資料以及技術採納證據。本分析全面檢驗了需求促進因素、臨床實踐趨勢、區域醫療基礎設施、手術流程、報銷考量以及競爭性技術發展趨勢,不依賴未經證實的市場規模估算或預測假設。
碎石設備市場正從分散的治療設備轉向整合、數據驅動的碎石管理模式。需求成長的促進因素包括復發性結石、對微創治療的偏好,以及雷射、衝擊波系統、影像技術、內視鏡配件和專用耗材的不斷改進。
The Lithotripsy Devices Market is projected to grow by USD 2.04 billion at a CAGR of 5.05% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 1.44 billion |
| Estimated Year [2026] | USD 1.51 billion |
| Forecast Year [2032] | USD 2.04 billion |
| CAGR (%) | 5.05% |
Lithotripsy devices are central to modern stone management, enabling noninvasive and minimally invasive fragmentation of kidney, ureteral, bladder, and selected biliary stones. The market spans extracorporeal shock wave lithotripsy systems, intracorporeal laser lithotripsy platforms, pneumatic and ultrasonic lithotripters, disposable fibers and probes, imaging-enabled consoles, and service models used across hospitals, ambulatory surgical centers, and specialty urology clinics.
Demand is supported by well-established clinical drivers: rising urolithiasis burden, recurrent stone disease, aging populations, obesity, diabetes, dehydration risk, dietary salt and animal-protein intake, and broader access to endourology. Clinical guidelines from major urology associations continue to position shock wave lithotripsy, ureteroscopy with laser lithotripsy, and percutaneous nephrolithotomy as core treatment pathways, making device selection increasingly tied to stone size, location, composition, anatomy, infection status, and provider expertise.
The lithotripsy devices landscape is shifting from capital-equipment-only purchasing toward integrated procedure ecosystems. Hospitals are evaluating platforms based not only on stone-free outcomes but also on operating room efficiency, fluoroscopy reduction, laser fiber utilization, device uptime, training support, infection-control compatibility, and total cost of ownership. This favors vendors that combine durable systems with consumables, software, service contracts, and clinical education.
Technology is also moving toward higher precision and lower procedural burden. High-power holmium:YAG lasers remain widely adopted, while thulium fiber laser systems have gained attention in peer-reviewed urology literature for fine dusting, energy efficiency, reduced retropulsion, and small-fiber compatibility. In extracorporeal shock wave lithotripsy, improved targeting, ultrasound guidance, pulse optimization, and patient-selection protocols are being used to optimize outcomes in appropriate stone cases while limiting unnecessary radiation exposure.
Artificial intelligence is beginning to influence lithotripsy through image interpretation, workflow automation, predictive analytics, and treatment planning. AI-enabled analysis of CT and ultrasound images can support stone detection, stone volume estimation, density assessment, skin-to-stone distance evaluation, and anatomic mapping, helping clinicians determine whether shock wave lithotripsy, ureteroscopic laser lithotripsy, or percutaneous intervention is most appropriate.
The cumulative impact is strongest where AI connects diagnostics, procedure guidance, and post-treatment follow-up. Algorithms that help predict fragmentation success, residual fragments, infection risk, and recurrence can improve patient selection, scheduling, and resource planning. However, adoption depends on validated clinical performance, representative training datasets, transparent data governance, interoperability with imaging and hospital information systems, cybersecurity safeguards, and compliance with medical device software regulations.
Asia-Pacific is one of the most dynamic arenas for lithotripsy devices, supported by expanding hospital infrastructure, high patient volumes, and increasing adoption of endourology in China, India, Japan, South Korea, Australia, and ASEAN markets. Public and private investments in tertiary care, medical tourism, specialist training, and diagnostic imaging are expanding access, although reimbursement variation, rural-urban gaps, and unequal distribution of advanced laser and shock wave systems remain important constraints.
North America remains a technology-leading region, led by the United States and Canada, where high procedure volumes, strong specialty networks, advanced imaging access, ambulatory surgery capabilities, and established reimbursement support adoption of ureteroscopic laser lithotripsy, shock wave lithotripsy, and PCNL-related devices. Europe demonstrates mature demand across Germany, France, Italy, Spain, and the United Kingdom, with procurement shaped by evidence-based clinical guidelines, hospital budget discipline, sustainability considerations, and strengthened medical device oversight under European regulatory frameworks.
Latin America, the Middle East, and Africa present selective but important opportunities. Brazil and Mexico anchor Latin American demand through large urban hospital systems, private care expansion, and growing access to minimally invasive urology. GCC countries in the Middle East are investing in high-acuity hospitals, specialist urology services, and premium surgical infrastructure, while broader African adoption is constrained by capital budgets, trained workforce availability, maintenance infrastructure, and uneven imaging access, creating demand for durable, serviceable, and cost-effective lithotripsy platforms.
ASEAN markets are moving toward wider adoption of ureteroscopy and laser lithotripsy as urban hospitals expand minimally invasive surgery capabilities, while procurement often prioritizes affordability, service responsiveness, consumables availability, and clinician training. The GCC is characterized by high healthcare investment, advanced hospital networks, medical tourism ambitions, and demand for premium urology systems, particularly in Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait.
The European Union shapes lithotripsy commercialization through harmonized regulatory oversight under the EU Medical Device Regulation, health technology assessment expectations, clinical evidence requirements, vigilance obligations, and sustainability-oriented procurement. BRICS markets are central to procedure-volume expansion because China, India, and Brazil combine large patient pools with expanding device access and domestic manufacturing capabilities, while Russia and South Africa add demand through public and private hospital channels despite procurement and access variability.
G7 countries represent a high-value innovation base where premium technologies, clinical evidence, post-market performance data, reimbursement scrutiny, and specialist-led purchasing strongly influence adoption. NATO-aligned healthcare systems, particularly in North America and Europe, emphasize supply resilience, cybersecurity for connected platforms, standardized maintenance frameworks, and interoperability, which are increasingly relevant as lithotripsy systems become digitally integrated with imaging, electronic records, and procedure-planning software.
The United States remains the leading single-country opportunity due to advanced urology networks, high imaging utilization, ambulatory surgery adoption, and strong uptake of laser lithotripsy across ureteroscopic stone procedures. Canada shows steady demand through hospital-based procurement and regional specialty centers, while Mexico benefits from urban private hospitals, expanding specialist access, and cross-border care dynamics. Brazil is Latin America's anchor market, supported by large metropolitan hospital systems, private-sector investment, and a growing base of trained endourologists.
In Europe, the United Kingdom emphasizes guideline-driven care and National Health Service procurement discipline, Germany remains a leading adopter of advanced endourology devices supported by strong hospital infrastructure, France combines public hospital demand with private specialty care, and Italy and Spain show sustained replacement and consumables demand across urology departments. Russia retains a sizable installed-base opportunity but faces procurement complexity, supply-chain sensitivity, and regional access variation.
In Asia-Pacific, China and India provide substantial growth potential through large patient populations, domestic manufacturing capacity, expanding tertiary care, and increasing access to endoscopic stone treatment, while Japan emphasizes precision, quality, safety, and regulatory compliance. Australia supports premium device adoption through specialist-led care pathways and advanced imaging access, and South Korea combines modern hospital infrastructure with strong digital health readiness and rapid uptake of minimally invasive technologies.
Industry leaders should align product portfolios with procedure-specific value: shock wave lithotripsy for appropriately selected noninvasive cases, high-performance laser lithotripsy for ureteroscopy, and ultrasonic or pneumatic systems for percutaneous procedures. Vendors should invest in training programs, simulation, clinical support, proctoring, and standardized protocols that improve outcomes, shorten learning curves, and support consistent use of lithotripsy devices across hospitals and ambulatory settings.
Commercial strategy should emphasize total cost of ownership, consumables reliability, device uptime, service coverage, preventive maintenance, and evidence-backed clinical performance. Companies should also prepare for AI-enabled imaging integration, cybersecurity requirements, regulatory scrutiny of software features, interoperability expectations, and growing demand for sustainable device lifecycle management, including repairability, responsible disposal, and efficient energy use.
This executive summary is developed using a structured secondary-research methodology that prioritizes peer-reviewed clinical literature, urology society guidelines, regulatory databases, public health sources, hospital procurement patterns, reimbursement references, and technology adoption evidence. The analysis triangulates demand drivers, clinical practice trends, regional healthcare infrastructure, procedure pathways, reimbursement considerations, and competitive technology developments without relying on unsupported sizing or forecasting assumptions.
Insights are validated through consistency checks across epidemiology, guideline-recognized treatment modalities, medical device regulations, and real-world healthcare delivery constraints. Market interpretation focuses on documented drivers such as stone disease burden, minimally invasive surgery adoption, CT and ultrasound availability, endourology training, service infrastructure, and regional access to specialist urology care.
The lithotripsy devices market is advancing from fragmented procedure equipment toward integrated, data-enabled stone management. Demand is anchored by recurrent stone disease, minimally invasive treatment preference, and continuous improvements in lasers, shock wave systems, imaging, endoscopic accessories, and procedure-specific consumables.
Future differentiation will depend on clinical evidence, workflow efficiency, AI readiness, service quality, regulatory compliance, cybersecurity, and regional adaptability. Organizations that combine reliable lithotripsy technology with training, digital integration, and outcome-focused commercial models will be better positioned across mature and emerging healthcare systems.